Kahn Brothers (Trades, Portfolio) sold shares of the following stocks during the second quarter:
The firm exited its position in Hologic Inc. (HOLX, Financial) with an impact of -0.87% on the portfolio.
The company manufactures diagnostics products, medical imaging systems and surgical products.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. The return on equity (ROE) of 31.67% and return on assets (ROA) of 9.86% are outperforming 78% of companies in the Global Medical Instruments and Supplies industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.18 is below the industry median of 1.55.
The company's largest shareholder among the gurus is the Vanguard Health Care Fund (Trades, Portfolio) with 1.26% of outstanding shares, followed by Jim Simons (Trades, Portfolio) with 0.44%, Kahn Brothers with 0.29% and the Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) with 0.18%.
The New York Times Co. (NYT, Financial) stake was reduced 7.07%, impacting the portfolio by -0.65%.
The media company distributes and creates news and information through its website and newspaper.
GuruFocus gives the company a profitability and growth rating of 5 out of 10. The ROE of 7.90% and ROA of 2.95% are outperforming 51% of companies in the Global Publishing industry. Financial strength has a rating of 6 out of 10. The cash-debt ratio of 2.36 is above the industry median of 1.60.
With 2.12% of outstanding shares, the firm is the company's largest guru shareholder, followed by Simons with 1.11%, Barrow, Hanley, Mewhinney & Strauss with 0.26%, Chuck Royce (Trades, Portfolio) with 0.17% and Steven Cohen (Trades, Portfolio) with 0.04%.
The Citigroup Inc. (C, Financial) position was reduced by 5.25%. The trade had an impact of -0.59% on the portfolio.
The bank has branches in more than 100 countries and over 200 million customer accounts. Its core business involves providing banking services, investment services, cash management and other related services.
GuruFocus gives the company a profitability and growth rating of 5 out of 10. The ROE of 6.11% and ROA of 0.84% are underperforming 69% of companies in the Global Banks - Global industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.58 is below the industry median of 2.09.
Barrow, Hanley, Mewhinney & Strauss is the company's largest shareholder among the gurus with 0.6% of outstanding shares, followed by Hotchkis & Wiley with 0.54%, First Pacific Advisors (Trades, Portfolio) with 0.41%, Bill Nygren (Trades, Portfolio) with 0.35% and Diamond Hill Capital (Trades, Portfolio) with 0.34%.
The firm reduced its holding of Pfizer Inc. (PFE, Financial) by 13.48%. The transaction had an impact of -0.53% on the portfolio.
The company manufactures pharmaceutical products such as vaccines, medicines and a wide range of health care products.
GuruFocus gives the company a profitability and growth rating of 7 out of 10. The ROE of 13.84% and ROA of 4.88% are outperforming 54% of companies in the Global Drug Manufacturers - Major industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.33 is below the industry median of 2.05.
The company's largest shareholder among the gurus is Barrow, Hanley, Mewhinney & Strauss with 0.78% of outstanding shares, followed by Ken Fisher (Trades, Portfolio) with 0.57%, Diamond Hill Capital with 0.19%, the T Rowe Price Equity Income Fund (Trades, Portfolio) with 0.17%, Lee Ainslie (Trades, Portfolio) with 0.17% and Pioneer Investments (Trades, Portfolio) with 0.16%.
The firm's Straight Path Communications Inc. (STRP, Financial) holding was reduced 18.62%, impacting the portfolio by -0.25%.
The telecom services company, along with its subsidiaries, markets wireless spectrum licenses and provides services to internet and telecommunications companies.
GuruFocus gives the company a profitability and growth rating of 3 out of 10. The ROE of -942.98% and ROA of -274.39% are underperforming 99% of companies in the Global Telecom Services industry. Financial strength has a rating of 4 out of 10. The cash-debt ratio of 1.42 is below the industry median of 0.41.
Paul Tudor Jones (Trades, Portfolio) is another notable guru shareholder of the company with 0.2% of outstanding shares, followed by Mario Gabelli (Trades, Portfolio) with 0.11% and Murray Stahl (Trades, Portfolio) with 0.02%.
The Navient Corp. (NAVI, Financial) position was reduced by 46.32%. The transaction had an impact of -0.16% on the portfolio.
The financial services company offers asset management and business processing services to clients in education, health care and government.
GuruFocus gives the company a profitability and growth rating of 4 out of 10. While the ROE of 15.76% is outperforming the sector, the ROA of 0.47% is underperforming 74% of companies in the Global Credit Services industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.01 is below the industry median of 1.44.
The company largest shareholder among the gurus is First Barrow, Hanley, Mewhinney & Strauss with 11.19% of outstanding shares, followed by Leon Cooperman (Trades, Portfolio) with 0.81%, Cohen with 0.07%, Gabelli with 0.05% and Ronald Muhlenkamp (Trades, Portfolio) with 0.01%.
The firm reduced its holding of New York Community Bancorp Inc. (NYCB, Financial) by 3.34%. The trade had an impact of -0.16% on the portfolio.
The bank operates over 200 branches in New York, Ohio, New Jersey, Florida and Arizona. It is one of the 25 largest bank holding companies in the U.S.
GuruFocus gives the company a profitability and growth rating of 4 out of 10. While the ROE of 7.06% is underperforming the sector, the ROA of 0.94% is outperforming 54% of companies in the Global Savings and Cooperative Banks industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.10 is below the industry median of 2.09.
Barrow, Hanley, Mewhinney & Strauss is the company's largest guru shareholder with 4.25% of outstanding shares, followed by Simons with 2.1% and CI Can Am Small Cap (Trades, Portfolio) with 0.06%.
The firm reduced its Bristol-Myers Squibb Co. (BMY, Financial) position by 31.49%, impacting the portfolio by -0.09%.
The company manufactures pharmaceutical products in several therapeutic areas, including cancer, HIV/AIDS, cardiovascular disease, diabetes and psychiatric disorders.
GuruFocus gives the company a profitability and growth rating of 6 out of 10. The ROE of 30.24% and ROA of 13.76% are outperforming 87% of companies in the Global Drug Manufacturers - Major industry. Financial strength has a rating of 6 out of 10. The cash-debt ratio of 0.79 is below the industry median of 2.05.
With 3.27% of outstanding shares, the Vanguard Health Care Fund has the largest position among the gurus, followed by Dodge & Cox with 1.8%, Simons with 0.82%, Spiros Segalas (Trades, Portfolio) with 0.49% and PRIMECAP Management (Trades, Portfolio) with 0.39%.
The firm closed its General Electric Co. (GE, Financial) position. The trade had an impact of -0.08% on the portfolio.
The industrial conglomerate manufactures products for several markets, including power and water, oil and gas, renewable energy, lighting, aviation, health care and transportation.
GuruFocus gives the company a profitability and growth rating of 5 out of 10. While the ROE of 9.31% is outperforming the sector, the ROA of 2.07% is underperforming 60% of companies in the Global Diversified Industrials industry. Financial strength has a rating of 5 out of 10. The cash-debt ratio of 0.63 is below the industry median of 1.01.
Fisher is the company's largest guru shareholder with 0.25% of outstanding shares, followed by First Pacific Advisors with 0.19%, Nygren with 0.16%, Steven Romick (Trades, Portfolio) with 0.14% and the T. Rowe Price Equity Income Fund with 0.12%.
Disclosure: I do not own any shares of any stocks mentioned in this article.
